Investors braced for bad earnings news from the biotech specialist, but Incyte surpassed those expectations late in the month.
News & Analysis: Incyte
INCY earnings call for the period ending March 31, 2019.
A fast-growing pharma and a leader in solar-power hardware have soared in 2019, but they're still buys for investors with a long-term mind-set.
INCY earnings call for the period ending December 31, 2018.
The biotech attracted more optimism from Wall Street ahead of its upcoming fourth-quarter report.
Biotech was a popular sector today. Find out why.
A number of companies suffered setbacks this year.
Checkpoint inhibitors remain top sellers, but it wasn’t all rosy news this year.
Here's what we can learn from the failure of Incyte's highly-touted cancer therapy.
INCY earnings call for the period ending September 30, 2018.